Skip to content

Reported November 6, 2025 · Before market open

Next report

Aug 6, 2026 (in a month)
Revenue estimate$2.2M
EPS estimate-$0.96

Financials

Q3 2025

Income statement

See full
Operating income-$30.0M-38.6%
Net income-$26.9M-53.5%
EPS (diluted)-$0.71-42.0%

Balance sheet

See full
Cash & equivalents$251.4M+539%
Total debt$11.9M+619%
Total equity$511.6M+58.3%
Total assets$535.3M+61.7%

Cash flow

See full
Operating cash flow-$17.5M-6.4%
CapEx$134.0K-4.3%
Free cash flow-$17.6M-6.3%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.37B+82.8%
Enterprise value$1.13B+58.8%

Returns & leverage

See full
Return on equity-23.4%
Debt / equity0.0×
Current ratio36.4×-9.5×

Versus estimates

Ask the moment Rapport Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Rapport Therapeutics, Inc. report Q3 2025 earnings?
Rapport Therapeutics, Inc. (RAPP) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Rapport Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Rapport Therapeutics, Inc. reported diluted EPS of $-0.71 for Q3 2025.
Did Rapport Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.77 by $0.06.
How did Rapport Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 42.0% from $-0.50.
Where can I find Rapport Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268072) and the 10-Q periodic report (0001193125-25-268096) directly on SEC EDGAR. The filing index links above go to sec.gov.